RedHill Biopharma Announced New Chinese Patent Notice Of Allowance For Opaganib In Combination With Immune Checkpoint Inhibitors As A Method Of Inducing An Anti-cancer Immune Response, Protecting Opaganib's Potential Use Through 2040
RedHill Biopharma Announced New Chinese Patent Notice Of Allowance For Opaganib In Combination With Immune Checkpoint Inhibitors As A Method Of Inducing An Anti-cancer Immune Response, Protecting Opaganib's Potential Use Through 2040
RedHill Biopharma宣佈Opaganib與免疫檢查點抑制劑聯合作為誘導抗癌免疫反應的方法獲得新的中國專利授權通知，保護Opaganib未來潛在的使用期限至2040年。
RedHill Biopharma Announced New Chinese Patent Notice Of Allowance For Opaganib In Combination With Immune Checkpoint Inhibitors As A Method Of Inducing An Anti-cancer Immune Response, Protecting Opaganib's Potential Use Through 2040
RedHill Biopharma宣佈Opaganib與免疫檢查點抑制劑聯合使用作爲引發抗癌免疫反應的一種方法獲得中國新專利通知，保護Opaganib的潛在用途至2040年。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。